Esteghamati et al. showed that metformin significantly reduced YKL-40, a novel marker of inflammation and oxidative stress in patients newly diagnosed with type 2 diabetes (T2D) [12, 13]. This evidence concerns the gene CHI3L1 and type 2 diabetes mellitus.